Esperion Therapeutics, Inc. 8-K

What Happened

• Esperion Therapeutics, Inc. held its 2026 annual meeting of stockholders on May 28, 2026 and filed a Form 8-K on June 1, 2026 reporting the meeting. The primary disclosed action was stockholder approval to amend the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan (the “2022 Plan”) to add 7,000,000 shares of common stock for issuance under the plan. The company’s definitive Proxy Statement relating to the Annual Meeting was filed April 16, 2026. The Plan Amendment and the 2022 Plan are included as Exhibit 10.1 to the 8-K. The filing was signed by President and CEO Sheldon L. Koenig.

Key Details

• Amendment approved increases available shares under the 2022 Plan by 7,000,000 shares of common stock.
• Annual meeting date: May 28, 2026; Proxy Statement filed April 16, 2026.
• Full text of the amended 2022 Plan is attached as Exhibit 10.1 to the Form 8-K (filed June 1, 2026).
• The action is reported under Items 5.02 and 5.07 of the Form 8-K; Exhibit disclosures are listed under Item 9.01.

Why It Matters

• The approved increase expands the pool of shares available for stock options, restricted stock, and other equity awards used for employee and director compensation. That supports hiring and retention but can lead to future dilution when awards are exercised or vest.
• Investors should review the attached Plan Amendment (Exhibit 10.1) and the company’s proxy materials for details on award types, vesting terms, and potential dilution impact. The 8-K does not include financial results or other material changes beyond the plan amendment and meeting disclosure.